BRPI0612591A2 - detecção de um antìgeno-alvo independentemente da presença ou da ausência de um anticorpo terapêutico correspondente - Google Patents
detecção de um antìgeno-alvo independentemente da presença ou da ausência de um anticorpo terapêutico correspondente Download PDFInfo
- Publication number
- BRPI0612591A2 BRPI0612591A2 BRPI0612591-3A BRPI0612591A BRPI0612591A2 BR PI0612591 A2 BRPI0612591 A2 BR PI0612591A2 BR PI0612591 A BRPI0612591 A BR PI0612591A BR PI0612591 A2 BRPI0612591 A2 BR PI0612591A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- target antigen
- therapeutic antibody
- sample
- therapeutic
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 129
- 239000000427 antigen Substances 0.000 title claims abstract description 101
- 102000036639 antigens Human genes 0.000 title claims abstract description 101
- 108091007433 antigens Proteins 0.000 title claims abstract description 101
- 238000001514 detection method Methods 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 49
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 41
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 41
- 241000282414 Homo sapiens Species 0.000 claims description 36
- 229940022353 herceptin Drugs 0.000 claims description 31
- 238000003018 immunoassay Methods 0.000 claims description 17
- 229960004641 rituximab Drugs 0.000 claims description 13
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 9
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 5
- 229940120638 avastin Drugs 0.000 claims 1
- 239000000523 sample Substances 0.000 description 41
- 230000000875 corresponding effect Effects 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 239000000872 buffer Substances 0.000 description 19
- 239000012723 sample buffer Substances 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- 101150029707 ERBB2 gene Proteins 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 239000012528 membrane Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000011148 porous material Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229960002087 pertuzumab Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 4
- 108010065524 CD52 Antigen Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102400001368 Epidermal growth factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 101100251687 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPP2B gene Proteins 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000012470 diluted sample Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000010324 immunological assay Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 101150047061 tag-72 gene Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940112129 campath Drugs 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940082789 erbitux Drugs 0.000 description 3
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 3
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- -1 resorfine Chemical compound 0.000 description 3
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 150000000918 Europium Chemical class 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- YNLCVAQJIKOXER-UHFFFAOYSA-N N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid Chemical compound OCC(CO)(CO)NCCCS(O)(=O)=O YNLCVAQJIKOXER-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- LWISPDYGRSGXME-YDHLFZDLSA-N biotin peg2 amine Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCOCCOCCN)SC[C@@H]21 LWISPDYGRSGXME-YDHLFZDLSA-N 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003712 glycosamine group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229950007308 satumomab Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- YNIRKEZIDLCCMC-UHFFFAOYSA-K trisodium;phosphate;hydrate Chemical compound [OH-].[Na+].[Na+].[Na+].OP([O-])([O-])=O YNIRKEZIDLCCMC-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05014618.2 | 2005-07-06 | ||
| EP05014618 | 2005-07-06 | ||
| EP06004447.6 | 2006-03-06 | ||
| EP06004447 | 2006-03-06 | ||
| PCT/EP2006/006524 WO2007003420A1 (en) | 2005-07-06 | 2006-07-05 | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0612591A2 true BRPI0612591A2 (pt) | 2010-11-23 |
Family
ID=36922121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0612591-3A BRPI0612591A2 (pt) | 2005-07-06 | 2006-07-05 | detecção de um antìgeno-alvo independentemente da presença ou da ausência de um anticorpo terapêutico correspondente |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20070009976A1 (enExample) |
| EP (2) | EP2194380A3 (enExample) |
| JP (1) | JP2008545145A (enExample) |
| KR (1) | KR20080016939A (enExample) |
| AR (1) | AR053948A1 (enExample) |
| AU (1) | AU2006265275A1 (enExample) |
| BR (1) | BRPI0612591A2 (enExample) |
| CA (1) | CA2613187A1 (enExample) |
| CR (1) | CR9635A (enExample) |
| EC (1) | ECSP088081A (enExample) |
| IL (1) | IL188317A0 (enExample) |
| MA (1) | MA29730B1 (enExample) |
| MX (1) | MX2008000277A (enExample) |
| MY (1) | MY157955A (enExample) |
| NO (1) | NO20076662L (enExample) |
| NZ (1) | NZ564471A (enExample) |
| RU (1) | RU2008103608A (enExample) |
| TW (1) | TWI312864B (enExample) |
| WO (1) | WO2007003420A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ522444A (en) * | 2000-05-19 | 2004-09-24 | Genentech Inc | Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy |
| SI1771482T1 (sl) * | 2004-07-22 | 2014-12-31 | Genentech, Inc. | Sestavek HER2 protitelesa |
| WO2007092545A2 (en) | 2006-02-07 | 2007-08-16 | The Board Of Trustees Of The Leland Stanford Junior University | Variable imaging arrangements and methods therefor |
| KR101134208B1 (ko) | 2004-10-01 | 2012-04-09 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 촬상 장치 및 그 방법 |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| NZ590431A (en) | 2005-02-23 | 2012-08-31 | Genentech Inc | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US8358354B2 (en) | 2009-01-26 | 2013-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Correction of optical abberations |
| CN101680897B (zh) | 2007-03-02 | 2013-11-13 | 健泰科生物技术公司 | 基于低her3表达预测对her二聚化抑制剂的响应 |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| MX2014004021A (es) | 2011-10-14 | 2014-04-30 | Genentech Inc | Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab. |
| KR101327542B1 (ko) * | 2012-03-15 | 2013-11-08 | 광주과학기술원 | 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법 |
| AU2012232949B2 (en) * | 2012-09-28 | 2014-07-03 | Willowtree Holdings Pty Ltd | Temporary bulkhead |
| RU2737727C2 (ru) | 2013-04-16 | 2020-12-02 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| SG11201608912VA (en) | 2014-04-25 | 2016-11-29 | Genentech Inc | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
| RS65871B1 (sr) | 2015-05-30 | 2024-09-30 | Hoffmann La Roche | Postupci lečenja her2-pozitivnog prethodno nelečenog metastatskog karcinoma dojke |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| US20180221481A1 (en) | 2016-12-28 | 2018-08-09 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
| TWI729259B (zh) | 2017-01-17 | 2021-06-01 | 美商建南德克公司 | 皮下her2 抗體調配物 |
| CN114984206A (zh) | 2017-03-02 | 2022-09-02 | 基因泰克公司 | Her2阳性乳腺癌的辅助治疗 |
| TW201902509A (zh) | 2017-04-24 | 2019-01-16 | 美商建南德克公司 | Erbb2/her2突變 |
| KR20230030621A (ko) | 2020-06-29 | 2023-03-06 | 제넨테크, 인크. | 퍼투주맙 + 트라스투주맙 고정 용량 조합 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2095818B (en) | 1981-03-27 | 1985-10-02 | Exxon Research Engineering Co | Staged adsorption/resorption heat pump |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP4124480B2 (ja) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
| IL129354A0 (en) | 1996-10-18 | 2000-02-17 | Genentech Inc | Anti-ErbB2 antibodies |
| EP2131198B1 (en) * | 2001-09-20 | 2013-03-27 | Board of Regents, The University of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays |
| PT2263691E (pt) * | 2002-07-15 | 2012-11-12 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4) |
-
2006
- 2006-06-29 US US11/477,772 patent/US20070009976A1/en not_active Abandoned
- 2006-06-29 MY MYPI20063118A patent/MY157955A/en unknown
- 2006-07-04 AR ARP060102872A patent/AR053948A1/es not_active Application Discontinuation
- 2006-07-04 TW TW095124248A patent/TWI312864B/zh active
- 2006-07-05 CA CA002613187A patent/CA2613187A1/en not_active Abandoned
- 2006-07-05 MX MX2008000277A patent/MX2008000277A/es not_active Application Discontinuation
- 2006-07-05 KR KR1020087000259A patent/KR20080016939A/ko not_active Ceased
- 2006-07-05 BR BRPI0612591-3A patent/BRPI0612591A2/pt not_active IP Right Cessation
- 2006-07-05 AU AU2006265275A patent/AU2006265275A1/en not_active Abandoned
- 2006-07-05 RU RU2008103608/15A patent/RU2008103608A/ru unknown
- 2006-07-05 NZ NZ564471A patent/NZ564471A/en unknown
- 2006-07-05 JP JP2008519853A patent/JP2008545145A/ja active Pending
- 2006-07-05 EP EP10157725A patent/EP2194380A3/en not_active Withdrawn
- 2006-07-05 WO PCT/EP2006/006524 patent/WO2007003420A1/en not_active Ceased
- 2006-07-05 EP EP06754671A patent/EP1902315A1/en not_active Withdrawn
-
2007
- 2007-12-20 IL IL188317A patent/IL188317A0/en unknown
- 2007-12-21 CR CR9635A patent/CR9635A/es not_active Application Discontinuation
- 2007-12-28 NO NO20076662A patent/NO20076662L/no not_active Application Discontinuation
-
2008
- 2008-01-04 EC EC2008008081A patent/ECSP088081A/es unknown
- 2008-02-01 MA MA30617A patent/MA29730B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2194380A3 (en) | 2010-07-14 |
| EP2194380A2 (en) | 2010-06-09 |
| CA2613187A1 (en) | 2007-01-11 |
| US20070009976A1 (en) | 2007-01-11 |
| AR053948A1 (es) | 2007-05-23 |
| IL188317A0 (en) | 2008-04-13 |
| TW200741203A (en) | 2007-11-01 |
| MA29730B1 (fr) | 2008-09-01 |
| EP1902315A1 (en) | 2008-03-26 |
| RU2008103608A (ru) | 2009-08-20 |
| AU2006265275A1 (en) | 2007-01-11 |
| KR20080016939A (ko) | 2008-02-22 |
| NZ564471A (en) | 2010-04-30 |
| CR9635A (es) | 2008-02-20 |
| MY157955A (en) | 2016-08-30 |
| JP2008545145A (ja) | 2008-12-11 |
| TWI312864B (en) | 2009-08-01 |
| NO20076662L (no) | 2008-04-03 |
| WO2007003420A1 (en) | 2007-01-11 |
| MX2008000277A (es) | 2008-03-24 |
| ECSP088081A (es) | 2008-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0612591A2 (pt) | detecção de um antìgeno-alvo independentemente da presença ou da ausência de um anticorpo terapêutico correspondente | |
| ES2705403T3 (es) | Ensayos para detectar la presencia o cantidad de un anticuerpo antifármaco | |
| US20020090662A1 (en) | Analytical method | |
| US10197581B2 (en) | Vitamin D assays | |
| JP3363466B2 (ja) | 酵素結合体を安定化する方法 | |
| EP3264085A1 (en) | Immunoassay method and assay reagent used in said method | |
| JP2018534568A (ja) | 小分子のためのサンドイッチアッセイ | |
| CN107533053A (zh) | L‑fabp的免疫测定方法以及用于所述方法的测定试剂 | |
| BRPI0519354B1 (pt) | método para detecção de um anticorpo terapêutico e uso de um anticorpo | |
| US20090005267A1 (en) | Immunoassay for cross-reacting substances | |
| CN103235125A (zh) | 莱克多巴胺、西马特罗二联胶体金试纸条及其制备方法与用途 | |
| WO2017039574A1 (en) | Vitamin d assays | |
| CN118515772A (zh) | 抗生物素单克隆抗体及其制备方法和应用 | |
| US20180246090A1 (en) | Immunoassay method and assay reagent used in said method | |
| US8021849B2 (en) | Methods and kits for the determination of sirolimus in a sample | |
| CN101213450A (zh) | 不论存在或不存在相对应的治疗用抗体而检测靶抗原 | |
| CN105209486B (zh) | 含有受体的经稳定的液体配制物 | |
| HK1115446A (en) | Detecting of a target antigen irrespective of the presenace or absence of a corresponding therapeutic antibody | |
| CN103207270A (zh) | 西马特罗胶体金试纸条及其制备方法与用途 | |
| Cernoch et al. | Production and analytical characterization of neopterin immunoreagents for biosensor developments | |
| KR102124260B1 (ko) | 신속 면역크로마토그래피법을 이용한 콜레라균 진단·탐지 키트 및 이를 위한 특이항체와 항체생산세포주 | |
| CN112695016A (zh) | 一株分泌组胺单克隆抗体杂交瘤细胞株及其应用 | |
| Ahmed | Elucidation of the Principles | |
| CN115057871A (zh) | 利福平半抗原衍生物、利福平完全抗原、利福平抗体及应用 | |
| CN111879934A (zh) | 一种犬癌胚抗原免疫梳、犬癌胚抗原检测试剂盒 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 6A ANUIDADE. |